U.S. patent application number 15/249598 was filed with the patent office on 2017-04-20 for single-dose administration of factor viia.
The applicant listed for this patent is Novo Nordisk HealthCare AG. Invention is credited to Ulla Hedner.
Application Number | 20170106060 15/249598 |
Document ID | / |
Family ID | 26892369 |
Filed Date | 2017-04-20 |
United States Patent
Application |
20170106060 |
Kind Code |
A1 |
Hedner; Ulla |
April 20, 2017 |
SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
Abstract
The present invention provides methods for preventing and/or
treating bleeding episodes by administering a single dose of a
Factor VIIa equivalent. Preferably, the single dose comprises
between about 150 and about 500 ug/kg Factor VIIa equivalent.
Inventors: |
Hedner; Ulla; (Malmoe,
SE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Novo Nordisk HealthCare AG |
Zurich |
|
CH |
|
|
Family ID: |
26892369 |
Appl. No.: |
15/249598 |
Filed: |
August 29, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14973837 |
Dec 18, 2015 |
|
|
|
15249598 |
|
|
|
|
14683392 |
Apr 10, 2015 |
|
|
|
14973837 |
|
|
|
|
12127917 |
May 28, 2008 |
9029324 |
|
|
14683392 |
|
|
|
|
10196902 |
Jul 16, 2002 |
7419949 |
|
|
12127917 |
|
|
|
|
60305720 |
Jul 16, 2001 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 38/4846 20130101;
A61K 38/37 20130101; A61K 38/4846 20130101; A61K 38/45 20130101;
A61P 7/04 20180101; C12Y 304/21021 20130101; A61K 45/06 20130101;
A61K 9/0019 20130101; A61K 2300/00 20130101 |
International
Class: |
A61K 38/48 20060101
A61K038/48; A61K 45/06 20060101 A61K045/06; A61K 9/00 20060101
A61K009/00 |
Claims
1. A method for treating a bleeding episode in a subject in need of
such treatment, said method comprising administering intravenously
to said subject a Factor VIIa equivalent, wherein said
administering is in a single dose and said dose comprises a
single-dose-effective amount of said Factor VIIa equivalent and
wherein, subsequent to said administration, no further Factor VIIa
equivalent is administered to said subject for a period of at least
4 hours.
2. A method as defined in claim 1, wherein said period is at least
about 24 hours.
3. A method as defined in claim 1, wherein said single dose is
administered over a period of less than about 5 minutes.
4. A method as defined in claim 1, wherein said
single-dose-effective amount comprises between about 300 and about
500 ug/kg Factor VIIa equivalent.
5. A method as defined in claim 1, wherein said Factor VIIa
equivalent exhibits at least about 30% of the coagulant activity of
Factor VIIa on a molar basis.
6. A method as defined in claim 1, wherein said Factor VIIa
equivalent is selected from the group consisting of: S52A-FVII,
S60A-FVII; L305V-FVII, L305V/M306D/D309S-FVII, L305I-VII,
L305T-FVII, F374P-FVII, V158T/M298Q-FVII, V158D/E296V/M298Q-FVII,
K337A-FVII, M298Q-FVII, V 158D/M298Q-FVII, L305V/K337A-FVII,
V158D/E296V/M298Q/L305V-FVII, V158D/E296V/M298Q/K337A-FVII,
V158D/E296V/M298Q/L305V/K337A-FVII, K157A-FVII, E296V-FVII,
E296V/M298Q-FVII, V158D/E296V-FVII, V158D/M298K-FVII, and
S336G-FVII; Factor VIIa that has been proteolytically cleaved
between residues 290 and 291; Factor VIIa that has been
proteolytically cleaved between residues 315 and 316; and oxidized
forms of Factor VIIa.
7. A method as defined in claim 1, further comprising
administering, in said single dose, or substantially simultaneously
with said single dose, a second coagulant agent.
8. A method as defined in claim 7, wherein said second coagulant
agent is selected from the group consisting of Factor VII, Factor
VIII, Factor IX, and Factor XIII
9. A method as defined in claim 1, further comprising administering
an anticoagulant, wherein said anticoagulant is administered in
said single dose, or substantially simultaneously with said single
dose.
10. A method for treating a bleeding episode, said method
comprising administering to a subject in need of such treatment (i)
a first amount of a Factor VIIa equivalent and (ii) a second amount
of second coagulant agent, wherein said first and second amounts
together comprise an aggregate effective amount for treating said
bleeding and said aggregate effective amount is administered in a
single dose.
11. A method as defined in claim 1, wherein said administering is
via a route selected from the group consisting of intravenous,
intramuscular, subcutaneous, mucosal, and pulmonary administration.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 14/973,837, filed Dec. 18, 2015, which is a continuation of
U.S. application Ser. No. 14/683,392, filed Apr. 10, 2015 (now
abandoned), which is a continuation of U.S. application Ser. No.
12/127,917, filed May 28, 2008 (now U.S. Pat. 9,029,324, issued May
12, 2015), which is a continuation of U.S. application Ser. No.
10/196,902 filed Jul. 16, 2002 (now U.S. Pat. 7,419,949, issued
Sep. 2, 2008), and claims priority under 35 U.S.C. 119 of U.S.
Application No. 60/305,720 filed on Jul. 16, 2001, the contents of
which are fully incorporated herein by reference.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted in ASCII format via EFS-Web and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on Aug. 23, 2016, is named 6361US03_SeqList.txt and is 4 kilobytes
in size.
FIELD OF THE INVENTION
[0003] The present invention relates to methods for preventing
and/or treating bleeding using coagulation factors.
BACKGROUND OF THE INVENTION
[0004] Factor VII is a plasma coagulation factor, which, once
activated to Factor VIIa, initiates the normal haemostatic process
by forming a complex with tissue factor (TF), a cell surface
glycoprotein that is exposed to the circulation as a result of
injury to the vessel wall.
[0005] Subsequently, the Factor VIIa-TF complex activates Factor IX
and Factor X into their activated forms (Factor IXa and Factor Xa,
respectively). Factor Xa converts limited amounts of prothrombin to
thrombin on the tissue factor-bearing cell. Thrombin activates
platelets and Factors V and VIII into Factors Va and VIIIa, both
cofactors in the further process leading to the full thrombin
burst. Thrombin finally converts fibrinogen to fibrin resulting in
formation of a fibrin clot. Fibrin clots formed in the presence of
high thrombin concentrations comprise a tighter network and are
more resistant to proteolysis than clots formed in lower
concentrations of thrombin. Accordingly, a full thrombin burst is
likely to be important for forming a hemostatic plug that is
resistant to fibrinolysis and thus to facilitate full hemostasis
and wound healing.
[0006] Factor VIIa, as well as Factor VIII and Factor IX, have been
used to control bleeding disorders that are caused by clotting
factor deficiencies (such as, e.g. haemophilia A and B or
deficiency of coagulation Factors XI or VII) or clotting factor
inhibitors. Factor VIIa has also been used to control excessive
bleeding caused by defective platelet function, thrombocytopenia or
von Willebrand' s disease.
[0007] Typically, however, patients are treated with multiple
injections or infusions of a coagulation factor before the bleeding
is stopped. In the case of Factor VIII and Factor IX
administration, a considerable number of injections are needed to
maintain haemostasis until the injury causing the bleeding is
completely healed. A quicker and more effective treatment, as well
as a reduction in the number of injections needed before the
bleeding is stopped, represent important benefit to such patients.
It would also be a considerable benefit to a patient needing
frequent injections or infusions with a haemostatic agent that the
injection frequency be reduced.
[0008] Thus, there is a need in the art for methods for preventing
and/or treating bleeding episodes that reduce the duration of
administration and provide a more rapid hemostasis.
SUMMARY OF THE INVENTION
[0009] The present invention relates to methods for preventing
and/or treating a bleeding episode in a subject in need of such
treatment, which are carried out by administering to the subject,
in a single dose, a single-dose-effective amount of Factor VIIa or
a Factor VIIa equivalent. Preferably, subsequent to the
administration, no further Factor VIIa or protein having Factor
VIIa coagulant activity is administered to the subject for an
interval of at least about 1 hour. In some embodiments, the
interval is at least about 4 hours; in other embodiments, the
interval is at least about 24 hours; and in some embodiments, no
further Factor VIIa or protein having Factor VIIa coagulant
activity is administered during the particular bleeding episode
that is being treated.
[0010] In some embodiments, the single-dose-effective amount
comprises between about 150 and about 500 ug/kg Factor VIIa or a
corresponding amount of a Factor VIIa equivalent; in other
embodiments, the single-dose-effective amount comprises between
about 200 and about 500 ug/kg; between about 250 and about 500
ug/kg; between about 300 and about 500 ug/kg; between about 350 and
500 ug/kg; between about 400 and about 500 ug/kg; between about 450
and about 500 ug/kg; and greater than 500 ug/kg, respectively, of
Factor VIIa or a corresponding amount of a Factor VIIa
equivalent.
[0011] In some embodiments, the Factor VIIa equivalent exhibits at
least about 30% of the coagulant activity of Factor VIIa on a molar
basis. Non-limiting examples of a Factor VIIa equivalent include
S52A-FVII, S60A-FVII; L305V-FVII, L305V/M306D/D309S-FVII,
L305I-FVII, L305T-FVII, F374P-FVII, V158T/M298Q-FVII,
V158D/E296V/M298Q-FVII, K337A-FVII, M298Q-FVII, V158D/M298Q-FVII,
L305V/K337A-FVII, V158D/E296V/M298Q/L305V-FVII,
V158D/E296V/M298Q/K337A-FVII, V158D/E296V/M298Q/L305V/K337A-FVII,
K157A-FVII, E296V-FVII, E296V/M298Q-FVII, V158D/E296V-FVII,
V158D/M298K-FVII, and S336G-FVII; Factor VIIa variants exhibiting
increased proteolytic stability as disclosed in U.S. Pat. No.
5,580,560; Factor VIIa that has been proteolytically cleaved
between residues 290 and 291 or between residues 315 and 316;
oxidized forms of Factor VIIa; Factor VII-sequence variants wherein
the amino acid residue in positions 290 and/or 291 (of SEQ ID
NO:1), preferably 290, have been replaced, and Factor VII-sequence
variants wherein the amino acid residue in positions 315 and/or 316
(of SEQ ID NO:1), preferably 315, have been replaced.
[0012] In some embodiments, the method further comprises
administering, with or substantially simultaneously with the single
dose, a second coagulant agent. Non-limiting examples of a second
coagulant agent include Factor VIII, Factor IX, and Factor
XIII.
[0013] In some embodiments, the invention provides a method for
treating a bleeding episode, which is carried out by administering
to a subject in need of such treatment (i) a first amount of Factor
VIIa or a Factor VIIa equivalent and (ii) a second amount of second
coagulant agent, wherein the first and second amounts together
comprise an aggregate effective amount for treating the bleeding
episode and the aggregate effective amount is administered in a
single dose.
[0014] In some embodiments, the Factor VIIa used in practicing the
invention is recombinant human Factor VIIa.
[0015] In one embodiment, the invention provides a method for
treating a bleeding episode, which is carried out by administering
to a human subject in need of such treatment an effective amount
for treating said bleeding of human Factor VIIa or a human Factor
VIIa equivalent, wherein:
[0016] (i) said effective amount is administered in a single dose
over a period of less than about 5 minutes;
[0017] (ii) said effective amount comprises between about 300 and
about 500 ug/kg human Factor VIIa or human Factor VIIa equivalent
or a corresponding amount of a Factor VIIa equivalent; and
[0018] (iii) subsequent to said administration, no further Factor
VIIa or Factor VIIa equivalent is administered to said subject for
a period of at least about 1 hour.
[0019] In practicing the present invention, administration may be
achieved by any mode of administration, including, without
limitation, intravenous, intramuscular, subcutaneous, mucosal, and
pulmonary routes of administration.
[0020] In another aspect, the invention provides a method for
preventing a bleeding episode, which is carried out by
administering to a human subject in need of such prevention an
effective amount for preventing the bleeding episode of human
Factor VIIa or a human Factor VIIa equivalent, wherein:
[0021] (i) the effective amount is administered in a single dose
over a period of less than about 5 minutes;
[0022] (ii) the effective amount comprises between about 250 and
about 500 ug/kg human Factor VIIa or human Factor VIIa equivalent
or a corresponding amount of a Factor VIIa equivalent; and
[0023] (iii) subsequent to the administration, no further Factor
VIIIa or Factor VIIIa equivalent is administered to said subject
for a period of at least about 1 hour.
[0024] In some embodiments, the subject suffers from hemophilia A
or B.
[0025] In some embodiments, the bleeding is joint bleeding.
[0026] In some embodiments, the subject has not been treated
therapeutically with an anticoagulant for at least about 48 hours
prior to administration of Factor VIIa or a Factor VIIIa
equivalent.
[0027] In some embodiments, the subject has not been treated
therapeutically with a Vitamin K antagonist for at least about 48
hours prior to said administering.
DETAILED DESCRIPTION OF THE INVENTION
[0028] The present invention relates to methods for preventing
and/or treating bleeding in animals, particularly in humans. The
invention is based on the discovery that administration of a single
dose comprising a predetermined amount of Factor VIIIa is effective
in treating bleeding episodes, including major bleeding episodes,
and can also be used to prevent an anticipated bleeding
episode.
[0029] Without wishing to be bound by theory, it is believed that
Factor VIIa enhances thrombin generation on tissue factor-bearing
cells and on activated platelets at the site of injury and that
administration of a single dose of Factor VIIIa according to the
present invention provides a full thrombin burst, thereby
facilitating the formation of a tight, strong fibrin network that
is relatively resistant to premature fibrinolysis and obviating the
need for further administration of Factor VIIa.
[0030] As used herein, prevention refers to prophylactic
administration of Factor VIIIa so as to minimize or inhibit an
anticipated bleeding episode, such as, e.g., prior to surgery.
Treatment refers to regulation of an already-occurring bleeding,
such as, for example, in trauma, with the purpose of inhibiting or
minimizing the bleeding. It will be understood that efficacy in
prevention and/or treatment according to the present invention
encompasses the absence of significant side-effects, including,
without limitation, disseminated intravascular coagulation (DIC),
that would counterindicate to those of ordinary skill in the art
the use of any particular therapeutic regimen.
[0031] Bleeding refers to extravasation of blood from any component
of the circulatory system. The term "bleeding episode" includes,
without limitation, bleeding (including, without limitation,
excessive, uncontrolled bleeding, i.e., haemorrhaging) in
connection with surgery or trauma, such as, for example, in
connection with acute haemarthroses (bleedings in joints), chronic
haemophilic arthropathy, haematomas, (e.g., muscular,
retroperitoneal, sublingual and retropharyngeal), bleedings in
other tissue, haematuria (bleeding from the renal tract), cerebral
haemorrhage, surgery (e.g., hepatectomy), dental extraction, and
gastrointestinal bleedings (e.g., UGI bleeds). Also included are
hemorrhages in organs such as the brain, inner ear region and eyes
with limited possibility for surgical haemostasis; as well as
hemorrhages in connection with biopsies of various organs (liver,
lung, tumour tissue, gastrointestinal tract) as well as
laparoscopic surgery. Common to these situations is the difficulty
in providing haemostasis using surgical techniques (such as, e.g.,
sutures or clips), which is also the case when bleeding is
diffuse.
[0032] In practicing the invention, Factor VIIa or a Factor VIIa
equivalent is administered to a patient as a single dose comprising
a single-dose-effective amount. Administration of a single dose
refers to administration of an entire dose of Factor VIIa as a
bolus over a period of less than about 5 minutes. In some
embodiments, the administration occurs over a period of less than
about 2.5 minutes, and, in some, over less than about 1 min.
[0033] A single-dose-effective amount of Factor VIIa or a Factor
VIIa equivalent refers to the amount of Factor VIIa or equivalent
which, when administered in a single dose according to the
invention, produces a measurable improvement in at least one
clinical parameter of haemostasis known to those of ordinary skill
in the art (see below). Typically, a single-dose effective amount
comprises at least 150 ug/kg Factor VIIa. In different embodiments,
a single-dose-effective amount of Factor VIIa comprises between
about 150-500 ug/kg; 250-500 ug/kg; 300-500 ug/kg; 350-500 ug/kg;
400-500 ug/kg; 450-500 ug/kg; or more than 500 ug/kg, respectively.
When Factor VIIa equivalents are administered according to the
present invention, a single-dose effective amount corresponding to
the above-cited amounts may be determined by comparing the
anticoagulant activity of the Factor VIIa equivalent with that of
Factor VIIa (see below) and adjusting the amount to be administered
proportionately.
[0034] It will be understood that a single-dose-effective amount of
Factor VIIa may vary according to the subject's haemostatic status,
which, in turn, may be reflected in one or more clinical
parameters, including, e.g., relative levels of circulating
coagulation factors; amount of blood lost; rate of bleeding;
hematocrit, and the like. It will be further understood that the
single-dose-effective amount may be determined by those of ordinary
skill in the art by routine experimentation, by constructing a
matrix of values and testing different points in the matrix.
[0035] In some embodiments, following administration of a
single-dose of Factor VIIa or a Factor VIIa equivalent according to
the invention, the patient receives no further Factor VIIa or
Factor VIIa equivalent for an interval of at least about 1 hour. In
some embodiments the post-administration interval is at least about
4 hours; in other embodiments, the post-administration interval is
at least about 24 hours. In still other embodiments, no further
Factor VIIa or Factor VIIa equivalent is administered to treat the
particular bleeding episode.
[0036] According to the invention, Factor VIIa or a Factor VIIa
equivalent may be administered by any effective route, including,
without limitation, intravenous, intramuscular, subcutaneous,
mucosal, and pulmonary routes of administration. Preferably,
administration is by an intravenous route.
[0037] Factor Vila and Factor Vila equivalents: In practicing the
present invention, any Factor VIla or equivalent may be used that
is effective in preventing or treating bleeding when administered
in a single dose. In some embodiments, the Factor VIla is human
Factor VIla, as disclosed, e.g., in U.S. Pat. No. 4,784,950
(wild-type Factor VII). The term "Factor VII" is intended to
encompass Factor VII polypeptides in their uncleaved (zymogen)
form, as well as those that have been proteolytically processed to
yield their respective bioactive forms, which may be designated
Factor VIIa. Typically, Factor VII is cleaved between residues 152
and 153 to yield Factor VIIa.
[0038] Factor VIIa equivalents include, without limitation, Factor
VII polypeptides that have either been chemically modified relative
to human Factor VIIa and/or contain one or more amino acid sequence
alterations relative to human Factor VIIa. Such equivalents may
exhibit different properties relative to human Factor VIIa,
including stability, phospholipid binding, altered specific
activity, and the like.
[0039] In one series of embodiments, a Factor VIIa equivalent
includes polypeptides that exhibit at least about 10%, preferably
at least about 30%, more preferably at least about 50%, and most
preferably at least about 70%, of the specific biological activity
of human Factor VIIa. For purposes of the invention, Factor VIIa
biological activity may be quantified by measuring the ability of a
preparation to promote blood clotting using Factor VII-deficient
plasma and thromboplastin, as described, e.g., in U.S. Pat. No.
5,997,864. In this assay, biological activity is expressed as the
reduction in clotting time relative to a control sample and is
converted to "Factor VII units" by comparison with a pooled human
serum standard containing 1 unit/ml Factor VII activity.
Alternatively, Factor VIIa biological activity may be quantified by
(i) measuring the ability of Factor VIIa or a Factor VIIa
equivalent to produce of Factor Xa in a system comprising TF
embedded in a lipid membrane and Factor X. (Persson et al., J.
Biol. Chem. 272:19919-19924, 1997); (ii) measuring Factor X
hydrolysis in an aqueous system (see, Example 5 below); (iii)
measuring the physical binding of Factor VIIa or a Factor VIIa
equivalent to TF using an instrument based on surface plasmon
resonance (Persson, FEBS Letts. 413:359-363, 1997) and (iv)
measuring hydrolysis of a synthetic substrate by Factor VIIa and/or
a Factor VIIIa equivalent.
[0040] Non-limiting examples of Factor VII-related polypeptides
having substantially the same or improved biological activity as
wild-type Factor VII include S52A-FVII, S60A-FVII (lino et al.,
Arch. Biochem. Biophys. 352: 182-192, 1998); L305V-FVII,
L305V/M306D/D309S-FVII, L305I-FVII, L305T-FVII, F374P-FVII,
V158T/M298Q-FVII, V158D/E296V/M298Q-FVII, K337A-FVII, M298Q-FVII,
V158D/M298Q-FVII, L305V/K337A-FVII, V158D/E296V/M298Q/L305V-FVII,
V158D/E296V/M298Q/K337A-FVII, V158D/E296V/M298Q/L305V/K337A-FVII,
K157A-FVII, E296V-FVII, E296V/M298Q-FVII, V158D/E296V-FVII,
V158D/M298K-FVII, and S336G-FVII; Factor VIIa variants exhibiting
increased proteolytic stability as disclosed in U.S. Pat. No.
5,580,560; Factor VIIa that has been proteolytically cleaved
between residues 290 and 291 or between residues 315 and 316
(Mollerup et al., Biotechnol. Bioeng. 48:501-505, 1995); oxidized
forms of Factor VIIa (Kornfelt et al., Arch. Biochem. Biophys.
363:43-54, 1999), Factor VII-sequence variants wherein the amino
acid residue in positions 290 and/or 291 (of SEQ ID NO:1),
preferably 290, have been replaced, and Factor VII-sequence
variants wherein the amino acid residue in positions 315 and/or 316
(of SEQ ID NO:1), preferably 315, have been replaced.
[0041] Preparations and formulations: The present invention
encompasses therapeutic administration of Factor VIIa or Factor
VIIa equivalents, which is achieved using formulations that
comprise Factor VIIa preparations. As used herein, a "Factor VII
preparation" refers to a plurality of Factor VIIa polypeptides or
Factor VIIa equivalent polypeptides, including variants and
chemically modified forms, that have been separated from the cell
in which they were synthesized, whether a cell of origin or a
recombinant cell that has been programmed to synthesize Factor VIIa
or a Factor VIIa equivalent.
[0042] Separation of polypeptides from their cell of origin may be
achieved by any method known in the art, including, without
limitation, removal of cell culture medium containing the desired
product from an adherent cell culture; centrifugation or filtration
to remove non-adherent cells; and the like.
[0043] Optionally, Factor VII polypeptides may be further purified.
Purification may be achieved using any method known in the art,
including, without limitation, affinity chromatography, such as,
e.g., on an anti-Factor VII antibody column (see, e.g., Wakabayashi
et al., J. Biol. Chem. 261:11097, 1986; and Thim et al., Biochem.
27:7785, 1988); hydrophobic interaction chromatography;
ion-exchange chromatography; size exclusion chromatography;
electrophoretic procedures (e.g., preparative isoelectric focusing
(IEF), differential solubility (e.g., ammonium sulfate
precipitation), or extraction and the like. See, generally, Scopes,
Protein Purification, Springer-Verlag, New York, 1982; and Protein
Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers,
New York, 1989. Following purification, the preparation preferably
contains less than about 10% by weight, more preferably less than
about 5% and most preferably less than about 1%, of non-Factor VII
proteins derived from the host cell.
[0044] Factor VII and Factor VII-related polypeptides may be
activated by proteolytic cleavage, using Factor XIIa or other
proteases having trypsin-like specificity, such as, e.g., Factor
IXa, kallikrein, Factor Xa, and thrombin. See, e.g., Osterud et
al., Biochem. 11:2853 (1972); Thomas, U.S. Pat. No. 4,456,591; and
Hedner et al., J. Clin. Invest. 71:1836 (1983). Alternatively,
Factor VII may be activated by passing it through an ion-exchange
chromatography column, such as Mono Q.RTM. (Pharmacia) or the like.
The resulting activated Factor VII may then be formulated and
administered as described below.
[0045] Pharmaceutical compositions or formulations for use in the
present invention comprise a Factor VIla preparation in combination
with, preferably dissolved in, a pharmaceutically acceptable
carrier, preferably an aqueous carrier or diluent. A variety of
aqueous carriers may be used, such as water, buffered water, 0.4%
saline, 0.3% glycine and the like. The preparations of the
invention can also be formulated into liposome preparations for
delivery or targeting to the sites of injury. Liposome preparations
are generally described in, e.g., U.S. Pat. Nos. 4,837,028,
4,501,728, and 4,975,282. The compositions may be sterilised by
conventional, well-known sterilisation techniques. The resulting
aqueous solutions may be packaged for use or filtered under aseptic
conditions and lyophilised, the lyophilised preparation being
combined with a sterile aqueous solution prior to
administration.
[0046] The compositions may contain pharmaceutically acceptable
auxiliary substances or adjuvants, including, without limitation,
pH adjusting and buffering agents and/or tonicity adjusting agents,
such as, for example, sodium acetate, sodium lactate, sodium
chloride, potassium chloride, calcium chloride, etc.
[0047] Combinations: The present invention encompasses combined
single-dose administration of an additional agent in concert with
Factor VIla or a Factor VIla equivalent. In some embodiments, the
additional agent comprises a coagulant, including, without
limitation, a coagulation factor such as, e.g., Factor VIII, Factor
IX, or Factor XIII; or an inhibitor of the fibrinolytic system,
such as, e.g., aprotinin, .epsilon.-aminocaproic acid or tranexamic
acid. In other embodiments, the additional agent comprises an
anticoagulant, including, without limitation, heparin, warfarin,
coumarin, and modified Factor VII polypeptides, such as, e.g.,
R152E-Factor VIIa (Wildgoose et al., Biochem 29:3413-3420, 1990),
S344A-Factor VIIa (Kazama et al., J. Biol. Chem. 270:66-72, 1995),
FFR-Factor VIIa (Hoist et al., Eur. J. Vasc. Endovasc. Surg.
15:515-520, 1998), Factor VIIa lacking the Gla domain, (Nicolaisen
et al., FEBS Letts. 317:245-249, 1993), and chemically modified
Factor VII polypeptides (U.S. Pat. No. 5,997,864).
[0048] It will be understood that, in embodiments comprising
single-dose administration of combinations of Factor VIIa with
other agents, the dosage of Factor VIIa or Factor VIIa equivalent
may on its own comprise a single-dose-effective amount.
Alternatively, the combination of Factor VIIa or equivalent and the
second agent may together comprise a single-dose-effect amount for
preventing or treating bleeding episodes.
[0049] Indications: The present invention encompasses single-dose
administration of Factor VIIa or a Factor VIIa equivalent to any
patient who either anticipates a bleeding episode or who is
actively experiencing a bleeding episode. Such patients include,
without limitation, those suffering from bleeding disorders that
are caused by clotting factor deficiencies (e.g. haemophilia A and
B, or deficiency of coagulation Factors XI or VII); clotting factor
inhibitors; defective platelet function; thrombocytopenia; or von
Willebrand's disease. The methods of the invention may also be
applied to patients who are about to undergo surgery, preferably
major surgery, whether or not they suffer from a bleeding disorder;
as well as trauma patients. Furthermore, any type of profuse
bleeding from the gastrointestinal tract, or any bleeding occurring
postoperatively (including that occurring in patients not suffering
from a bleeding disorder) may benefit from treatment according to
the present invention.
[0050] In some embodiments, the invention does not encompass
administration of Factor VIIa or equivalent to patients undergoing
minor surgery. In other embodiments, the invention does not
encompass administration of Factor VIIIa or equivalent to patients
not suffering from a clotting disorder who had been administered an
anticoagulant (such as, e.g., acetocoumerol) within 48 hours prior
to Factor VIIIa administration. In other embodiments, the invention
does not encompass administration of Factor VIIIa or equivalent to
patients not suffering from a clotting disorder who had been
administered a Vitamin K antagonist within 48 hours prior to Factor
VIIIa administration.
[0051] The present invention also provides the benefit of allowing
a patient to self-administer an effective dose of Factor VIIIa or a
Factor VIIIa equivalent in order to facilitate effective management
of anticipated or current bleeding episodes.
[0052] Many variations of the present invention will suggest
themselves to those skilled in the art in light of the above
detailed description. Such obvious variations are within the full
intended scope of the invention.
[0053] All patents, patent applications, and literature references
referred to herein are hereby incorporated by reference in their
entirety.
[0054] The following examples are intended as non-limiting
illustrations of the present invention.
EXAMPLE 1
High-Dose Factor VIIa Administration
[0055] Patients suffering from hemophilia (including, e.g.,
patients with clotting factor inhibitors, acquired inhibitor
patients, patients suffering from Factor VII deficiency, and
patients suffering from von Willebrands disease) are enrolled in a
registry that tracks the outcome of bleeding episodes whose
treatment includes bolus administration of Factor VIIIa.
[0056] The bleeding episodes are characterized as spontaneous,
related to traumatic injury, or other (including, e.g., surgical or
dental procedures). The dosage groups are characterized as <100
ug/kg; 100-150 ug/kg; 150-200 ug/kg; and >200 ug/kg. Responses
to treatment (as assessed at 72 h) are characterized as cessation
of bleeding, slowing of bleeding; or no response.
EXAMPLE 2
Single High-Dose Factor VIIa Administration
Description of Clinical Trial:
[0057] A randomized, multicenter, cross-over, double-blind study is
performed to evaluate the efficacy and safety of Factor VIIIa (by
two different blinded dose schedules) in producing hemostasis in
joint bleeds in a home-treatment setting. Subjects with congenital
hemophilia A or B and inhibitors to Factor VIII or Factor IX
receive treatment and are assessed for at least 9 hours after the
dosing. The success or failure of the treatment is ascertained
using a pilot algorithm to assess changes in pain and joint
mobility. rFVIIa will be given as an intravenous bolus injection,
either at 270 .mu.g/kg body weight dose at hour 0, or at 90
.mu.g/kg body weight doses given at hours 0, 3 and 6 and placebo
solutions will be administered to blind subject as to the dose
regimen of rFVIIa being administered. If additional doses of Factor
VIIIa are administered within the first 9 hours to achieve
hemostasis, then the treatment efficacy is graded as a failure.
Trial Population:
[0058] Twenty-four patients with congenital hemophilia A or B and
inhibitors to factor VIII or IX have been enrolled in this trial.
Patients must have experienced two or more mild or moderate joint
bleeds during the past 12 months.
Assessments
[0059] Treatment efficacy is based on the evaluation of pain, joint
mobility and measure of circumference of the elbow or knee at the
midpoint of the joint in extension. These variables are graded and
entered in the diary by the patient/caregiver. Pain and mobility
are assessed as more, no difference or less than before the
treatment and circumference is measured in millimeters. An
independent blinded committee reviews the diary data on pain and
joint mobility and judges the response to treatment as success or
failure based on a pilot algorithm developed for this study.
Sequence CWU 1
1
11406PRTHomo sapiensMISC_FEATURE(1)..(406)Xaa= 4-carboxyglutamic
acid (gamma- carboxyglutamate) 1Ala Asn Ala Phe Leu Xaa Xaa Leu Arg
Pro Gly Ser Leu Xaa Arg Xaa 1 5 10 15 Cys Lys Xaa Xaa Gln Cys Ser
Phe Xaa Xaa Ala Arg Xaa Ile Phe Lys 20 25 30 Asp Ala Xaa Arg Thr
Lys Leu Phe Trp Ile Ser Tyr Ser Asp Gly Asp 35 40 45 Gln Cys Ala
Ser Ser Pro Cys Gln Asn Gly Gly Ser Cys Lys Asp Gln 50 55 60 Leu
Gln Ser Tyr Ile Cys Phe Cys Leu Pro Ala Phe Glu Gly Arg Asn 65 70
75 80 Cys Glu Thr His Lys Asp Asp Gln Leu Ile Cys Val Asn Glu Asn
Gly 85 90 95 Gly Cys Glu Gln Tyr Cys Ser Asp His Thr Gly Thr Lys
Arg Ser Cys 100 105 110 Arg Cys His Glu Gly Tyr Ser Leu Leu Ala Asp
Gly Val Ser Cys Thr 115 120 125 Pro Thr Val Glu Tyr Pro Cys Gly Lys
Ile Pro Ile Leu Glu Lys Arg 130 135 140 Asn Ala Ser Lys Pro Gln Gly
Arg Ile Val Gly Gly Lys Val Cys Pro 145 150 155 160 Lys Gly Glu Cys
Pro Trp Gln Val Leu Leu Leu Val Asn Gly Ala Gln 165 170 175 Leu Cys
Gly Gly Thr Leu Ile Asn Thr Ile Trp Val Val Ser Ala Ala 180 185 190
His Cys Phe Asp Lys Ile Lys Asn Trp Arg Asn Leu Ile Ala Val Leu 195
200 205 Gly Glu His Asp Leu Ser Glu His Asp Gly Asp Glu Gln Ser Arg
Arg 210 215 220 Val Ala Gln Val Ile Ile Pro Ser Thr Tyr Val Pro Gly
Thr Thr Asn 225 230 235 240 His Asp Ile Ala Leu Leu Arg Leu His Gln
Pro Val Val Leu Thr Asp 245 250 255 His Val Val Pro Leu Cys Leu Pro
Glu Arg Thr Phe Ser Glu Arg Thr 260 265 270 Leu Ala Phe Val Arg Phe
Ser Leu Val Ser Gly Trp Gly Gln Leu Leu 275 280 285 Asp Arg Gly Ala
Thr Ala Leu Glu Leu Met Val Leu Asn Val Pro Arg 290 295 300 Leu Met
Thr Gln Asp Cys Leu Gln Gln Ser Arg Lys Val Gly Asp Ser 305 310 315
320 Pro Asn Ile Thr Glu Tyr Met Phe Cys Ala Gly Tyr Ser Asp Gly Ser
325 330 335 Lys Asp Ser Cys Lys Gly Asp Ser Gly Gly Pro His Ala Thr
His Tyr 340 345 350 Arg Gly Thr Trp Tyr Leu Thr Gly Ile Val Ser Trp
Gly Gln Gly Cys 355 360 365 Ala Thr Val Gly His Phe Gly Val Tyr Thr
Arg Val Ser Gln Tyr Ile 370 375 380 Glu Trp Leu Gln Lys Leu Met Arg
Ser Glu Pro Arg Pro Gly Val Leu 385 390 395 400 Leu Arg Ala Pro Phe
Pro 405
* * * * *